Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Health And Human Services was posted on April 10, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

In Vitro Assessments of Antimicrobial Activity

Closed
75N93024R00024Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
Solicitation # RFA-AI-28-012
The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Grant
Immune Tolerance Network (UM1 Clinical Trial Required)
Solicitation # RFA-AI-28-005
The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

in 3 months
NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 25 days
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

5 days ago

DEADLINE

in 3 days

General Info

Contract Value

$2,500

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Bethesda, MD, USA

Set-Aside

NONE

Awardee

ASRT, INC.

Award Issued Date

Documents

21

75N93024R00024 Amendment Two - In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first2 pages · amendment
High

75N93024R00024 - In Vitro Assessments of Antimicrobial Activity (IVAAA)

PDF, High priority: read this first128 pages · rfp
High

Amendment One to RFP 75N93024R00024 In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first3 pages · amendment
High

Attachment 11 - Summary of Related Activities

PDF, High priority: read this first1 page · specifications
High

Attachment 12: Additional Technical Proposal Instructions

PDF, High priority: read this first6 pages · specifications
High

Attachment 13: Additional Business Proposal Instructions - In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first5 pages · rfp
High

Attachment 3: Base IDIQ Statement of Work - In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first8 pages · sow
High

HHSAR 352.223-70 Safety and Health

PDF, High priority: read this first2 pages · specifications
High

RFP 75N93024R00024 Attachment 1 - Packaging and Delivery of Proposals

PDF, High priority: read this first2 pages · submission-instructions
High

Sample Task Order A01: In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first6 pages · sow
High

Sample Task Order A-02: Determination of In Vitro Efficacy of Antitoxin Candidates

PDF, High priority: read this first5 pages · sow
High

Sample Task Order B-01: Determination of In Vitro Efficacy of Antiviral Candidates

PDF, High priority: read this first6 pages · sow
High

Sample Task Order C-01: In Vitro Assessments of Antimicrobial Activity

PDF, High priority: read this first5 pages · sow
High

Sample Task Order D-01: Development of a Method of In Vitro Culture

PDF, High priority: read this first4 pages · sow
High

Technical Proposal Cost Summary of Labor and Direct Costs

PDF, High priority: read this first1 page · specifications
High

Attachment 17 - Offeror Points of Contact

PDF, Low priority1 page · other
Low

Attachment 18 - Disclosure of Lobbying Activities (SF-LLL)

PDF, Low priority1 page · other
Low

HHS Industry User Guide for Subcontracting Plan Reviews

PDF, Low priority5 pages · other
Low

NIH-2043 Proposal Summary and Data Record

PDF, Low priority1 page · other
Low

NIH(RC)-2 Invoice Instructions for Fixed-Price Contracts

PDF, Low priority3 pages · other
Low

NIH(RC)-4 Invoice/Financing Request and Contract Financial Reporting Instructions

PDF, Low priority7 pages · specifications
Low

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

5 updates
PhaseClosed
Posted

Sources Sought

Type Changed

Sources Sought → Presolicitation

Deadline changed

Response deadline changed from Dec 27, 2024 to Dec 30, 2024.

Type Changed

Presolicitation → Solicitation

Notice updated

The notice description changed.

Notice updated

The notice description changed.

Response Deadline

Deadline has passed

Deadline changed

Response deadline changed from Mar 10, 2025 to Mar 24, 2025.

Notice updated

Response deadline changed from Mar 24, 2025 to Apr 24, 2025. The notice description changed.

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid
Contacts2 people available
OfficeBETHESDA, MD, 20892, USA
Office AddressBETHESDA, MD, 20892, USA
Contacts
Alexander Beraud

Full Description

Show more
AMENDMENT TWO The purpose of Amendment Two is to: 1. Respond to questions received regarding this solicitation. ______________________________________________________________________ AMENDMENT ONE The purpose of Amendment One is to: 1. Provide a cut-off date for submission of questions; 2. Provide updated instructions for the Proposal Intent Response Sheet; 3. Clarify submission instructions to eCPS; and 4. Respond to questions received regarding this solicitation. ______________________________________________________________________ Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement to support in vitro testing assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases. Description NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide capability in a broad range of in vitro testing capabilities to assess promising candidate countermeasures against the more than 270 infectious agents and vectors that are within the purview of DMID. In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data to be used by NIAID partners at other agencies within the Department of Health and Human Services. Such data will facilitate the advancement of promising candidate medical countermeasures against priority emerging and bioterror infectious agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile. In 2019, fourteen (14) institutions were awarded base contracts under the In Vitro Assessments of Antimicrobial Activity IDIQ contract program. Its overarching goal was to provide broad capability in in vitro methods to evaluate activity of candidate countermeasures against the full range of infectious agents in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging threats such as SARS-CoV-2 and other emergency preparedness priorities. NIAID anticipates awarding multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas described below. Offerors may submit to multiple Task Areas where they are capable to best meet the overall Task Area requirements, however, they must submit separate proposals for each of these Task Areas. Offerors will be considered for contracts only in the Task Area(s) included in their proposal(s), and successful Contractors may compete for task orders only in the Task Area(s) in which they are selected for award. Sample Task Orders will be provided in the Request for Proposal (RFP) solely to evaluate Offeror responses and capabilities. The Task Areas of this solicitation are as follows: Task Area A - Bacteria, Fungi, and Toxins Task Area B - Viruses Task Area C - Parasites and Vectors Task Area D - New Techniques to Culture Difficult-to-Grow Pathogens The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise, or facilities required to perform all activities set forth in the Statement of Work. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through subcontracts, partnership or consortia agreements, and/or use of consultants. However, Contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. Any responsible offeror may submit a proposal that will be considered by the Agency. This RFP will be available electronically on/about December 30, 2024, and may be accessed through SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit." Follow the "How to Submit an Electronic Proposal" instructions provided on the eCPS website at: https://ecps.nih.gov/home/howto. Please note that creating an account to submit may take up to three (3) business days. Please apply for a new account early to allow enough time for the registration process.

More opportunities from Department Of Health And Human Services → National Institutes Of Health Niaid

Same awarding agency

NAICS: 541715
Federal
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases
Solicitation # HHS-NIH-NIAID-BAA2026-1
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals under Broad Agency Announcement HHS-NIH-NIAID-BAA2026-1 to advance the research and development of medical interventions for infectious diseases. This initiative focuses on three primary research areas: the development of needle-free vaccine candidates through early-phase clinical trials; the creation of safe and effective therapeutic candidates for serious infectious diseases, including those resistant to current antimicrobial therapy; and the innovation of in vitro diagnostic technology platforms capable of rapid, automated detection of a broad panel of priority viral pathogens. The program emphasizes alignment with NIH priorities regarding biosafety, biosecurity, and the use of non-animal testing methods. Proposals must be submitted electronically via the NIAID eCPS website by December 8, 2026, at 3:00 PM Eastern Time. Technical proposals are limited to 75 pages and will be evaluated by a peer review group based on technical merit, with the technical plan and personnel qualifications being of paramount consideration. Awards are not based on a common Statement of Work; instead, offerors must propose their own technical plans, milestones, and cost structures using a base and option period format. The resulting contracts will require an accounting system compliant with generally accepted accounting principles and will involve rigorous government inspection and acceptance based on the successful completion of critical milestones.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

12 days ago

DEADLINE

in about 2 months
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS